Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 2/20 | 0.46 |
| ▸ | TOP2A | P11388 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710802 | 0.90 | MAPKAPK2 (0.56) | MAP3K8MAPKAPK2ACVR1 | |
| SCHEMBL4711945 | 0.83 | MAPKAPK2 (0.48) | MAP3K8ALDH1A1MAPKAPK2 | |
| SCHEMBL4715165 | 0.82 | HTT (0.51) | MAP3K8SMN1; SMN2MAPKAPK2 | |
| SCHEMBL5615107 | 0.74 | AKT1 (0.67) | MAP3K8PIK3CDPIK3CAALDH1A1 | |
| SCHEMBL2247254 | 0.74 | MAP3K8 (0.54) | MAP3K8MTORPIK3CDPIK3CAACVR1 | |
| SCHEMBL29330400 | 0.72 | SYK (0.56) | MAPKAPK2ACVR1 | |
| SCHEMBL4141098 | 0.72 | MAPKAPK2 (0.82) | MAPKAPK2 | |
| SCHEMBL2033020 | 0.72 | PIK3CA (0.48) | JAK1MAP3K8MTORPIK3CDPIK3CA | |
| SCHEMBL2037912 | 0.71 | FGFR1 (0.58) | MAP3K8SMN1; SMN2 | |
| SCHEMBL4714182 | 0.70 | HTR7 (0.54) | MAP3K8ALDH1A1HSD17B10ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262021-A1 | [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | claimed |
| EP-1687305-B1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-09 | — | — | EP | claimed |
| JP-2007511575-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1687305-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | claimed |
| US-20080262021-A1 | [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1687305-B1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1687305-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262021-A1 | [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia | ABL1, MAP4K2, MAP3K1 | JAK1 30/4885FYN 518/4885MAP3K8 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.